Information Technology Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
WAY vs UNH vs JPM vs CVS vs CI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Banks - Diversified
Medical - Healthcare Plans
Medical - Healthcare Plans
WAY vs UNH vs JPM vs CVS vs CI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Information Technology Services | Medical - Healthcare Plans | Banks - Diversified | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $3.60B | $370.80B | $896.00B | $130.09B | $78.57B |
| Revenue (TTM) | $1.16B | $449.71B | $280.33B | $407.90B | $277.94B |
| Net Income (TTM) | $126M | $12.04B | $57.05B | $2.93B | $6.29B |
| Gross Margin | 65.2% | 18.8% | 60.0% | 13.9% | 9.3% |
| Operating Margin | 24.3% | 4.2% | 25.9% | 1.5% | 3.4% |
| Forward P/E | 11.4x | 22.2x | 14.4x | 13.8x | 9.8x |
| Total Debt | $1.50B | $78.39B | $942.38B | $93.59B | $31.46B |
| Cash & Equiv. | $61M | $24.36B | $343.34B | $8.51B | $7.68B |
WAY vs UNH vs JPM vs CVS vs CI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 24 | Jun 26 | Return |
|---|---|---|---|
| Waystar Holding Cor… (WAY) | 100 | 87.2 | -12.8% |
| UnitedHealth Group … (UNH) | 100 | 80.2 | -19.8% |
| JPMorgan Chase & Co. (JPM) | 100 | 158.6 | +58.6% |
| CVS Health Corporat… (CVS) | 100 | 172.6 | +72.6% |
| Cigna Corporation (CI) | 100 | 90.1 | -9.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WAY vs UNH vs JPM vs CVS vs CI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
WAY ranks third and is worth considering specifically for growth exposure.
- Rev growth 16.5%, EPS growth 5.7%, 3Y rev CAGR 16.0%
- 16.5% revenue growth vs JPM's 3.3%
UNH is the clearest fit if your priority is income & stability.
- Dividend streak 16 yrs, beta 0.61, yield 2.1%
JPM is the clearest fit if your priority is long-term compounding.
- 465.8% 10Y total return vs CI's 158.0%
- 20.4% margin vs CVS's 0.7%
CVS carries the broadest edge in this set and is the clearest fit for defensive.
- Beta 0.19, yield 2.6%, current ratio 0.84x
- Beta 0.19 vs JPM's 0.94, lower leverage
- 2.6% yield, vs UNH's 2.1%, (1 stock pays no dividend)
- +57.7% vs WAY's -52.6%
CI is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.
- Lower volatility, beta 0.40, Low D/E 75.1%, current ratio 0.85x
- Lower P/E (9.8x vs 22.2x)
- 4.1% ROA vs CVS's 1.1%, ROIC 10.4% vs 5.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.5% revenue growth vs JPM's 3.3% | |
| Value | Lower P/E (9.8x vs 22.2x) | |
| Quality / Margins | 20.4% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.19 vs JPM's 0.94, lower leverage | |
| Dividends | 2.6% yield, vs UNH's 2.1%, (1 stock pays no dividend) | |
| Momentum (1Y) | +57.7% vs WAY's -52.6% | |
| Efficiency (ROA) | 4.1% ROA vs CVS's 1.1%, ROIC 10.4% vs 5.0% |
WAY vs UNH vs JPM vs CVS vs CI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
WAY vs UNH vs JPM vs CVS vs CI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
CI leads 2 • CVS leads 1 • WAY leads 0 • UNH leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 388.8x WAY's $1.2B. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to CVS's 0.7%. On growth, WAY holds the edge at +22.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.2B | $449.7B | $280.3B | $407.9B | $277.9B |
| EBITDAEarnings before interest/tax | $430M | $23.2B | $81.4B | $10.5B | $12.1B |
| Net IncomeAfter-tax profit | $126M | $12.0B | $57.0B | $2.9B | $6.3B |
| Free Cash FlowCash after capex | $294M | $19.7B | $100.9B | $7.4B | $7.7B |
| Gross MarginGross profit ÷ Revenue | +65.2% | +18.8% | +60.0% | +13.9% | +9.3% |
| Operating MarginEBIT ÷ Revenue | +24.3% | +4.2% | +25.9% | +1.5% | +3.4% |
| Net MarginNet income ÷ Revenue | +10.9% | +2.7% | +20.4% | +0.7% | +2.3% |
| FCF MarginFCF ÷ Revenue | +25.4% | +4.4% | +36.0% | +1.8% | +2.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.4% | +2.0% | — | +6.2% | +4.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +37.5% | +0.7% | +16.0% | +63.1% | +29.1% |
Valuation Metrics
CI leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 13.4x trailing earnings, CI trades at a 82% valuation discount to CVS's 73.4x P/E. On an enterprise value basis, CI's 8.7x EV/EBITDA is more attractive than JPM's 18.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3.6B | $370.8B | $896.0B | $130.1B | $78.6B |
| Enterprise ValueMkt cap + debt − cash | $5.0B | $424.8B | $1.50T | $215.2B | $102.4B |
| Trailing P/EPrice ÷ TTM EPS | 30.74x | 30.88x | 16.00x | 73.35x | 13.44x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.42x | 22.21x | 14.40x | 13.78x | 9.79x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.90x | — | — |
| EV / EBITDAEnterprise value multiple | 12.39x | 18.21x | 18.36x | 14.35x | 8.70x |
| Price / SalesMarket cap ÷ Revenue | 3.27x | 0.83x | 3.20x | 0.32x | 0.29x |
| Price / BookPrice ÷ Book value/share | 0.95x | 3.66x | 2.47x | 1.72x | 1.89x |
| Price / FCFMarket cap ÷ FCF | 12.70x | 23.07x | 8.88x | 16.66x | 9.37x |
Profitability & Efficiency
CI leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $4 for WAY. WAY carries lower financial leverage with a 0.39x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.5% | +11.5% | +15.9% | +3.9% | +15.1% |
| ROA (TTM)Return on assets | +2.4% | +3.9% | +1.3% | +1.1% | +4.1% |
| ROICReturn on invested capital | +4.2% | +9.2% | +4.5% | +5.0% | +10.4% |
| ROCEReturn on capital employed | +5.2% | +9.7% | +8.9% | +6.1% | +9.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.39x | 0.77x | 2.60x | 1.24x | 0.75x |
| Net DebtTotal debt minus cash | $1.4B | $54.0B | $599.0B | $85.1B | $23.8B |
| Cash & Equiv.Liquid assets | $61M | $24.4B | $343.3B | $8.5B | $7.7B |
| Total DebtShort + long-term debt | $1.5B | $78.4B | $942.4B | $93.6B | $31.5B |
| Interest CoverageEBIT ÷ Interest expense | 3.51x | 4.71x | 0.74x | 2.11x | 6.77x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $9,058 for WAY. Over the past 12 months, CVS leads with a +57.7% total return vs WAY's -52.6%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs UNH's -4.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -40.2% | +22.1% | -0.5% | +28.9% | +7.9% |
| 1-Year ReturnPast 12 months | -52.6% | +31.0% | +21.8% | +57.7% | -3.6% |
| 3-Year ReturnCumulative with dividends | -9.4% | -12.0% | +138.2% | +53.6% | +18.1% |
| 5-Year ReturnCumulative with dividends | -9.4% | +11.7% | +118.2% | +35.0% | +35.3% |
| 10-Year ReturnCumulative with dividends | -9.4% | +236.1% | +465.8% | +29.5% | +158.0% |
| CAGR (3Y)Annualised 3-year return | -3.2% | -4.2% | +33.6% | +15.4% | +5.7% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.19 beta — it tends to amplify market swings less than JPM's 0.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 99.2% from its 52-week high vs WAY's 45.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.84x | 0.61x | 0.94x | 0.19x | 0.40x |
| 52-Week HighHighest price in past year | $41.47 | $415.96 | $337.25 | $102.77 | $338.89 |
| 52-Week LowLowest price in past year | $17.89 | $234.60 | $262.71 | $58.50 | $239.51 |
| % of 52W HighCurrent price vs 52-week peak | +45.2% | +98.2% | +95.1% | +99.2% | +87.9% |
| RSI (14)Momentum oscillator 0–100 | 40.3 | 66.5 | 59.1 | 72.6 | 59.4 |
| Avg Volume (50D)Average daily shares traded | 2.4M | 7.2M | 7.0M | 7.6M | 1.4M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: WAY as "Buy", UNH as "Buy", JPM as "Buy", CVS as "Buy", CI as "Buy". Consensus price targets imply 90.0% upside for WAY (target: $36) vs 1.6% for CVS (target: $104). For income investors, CVS offers the higher dividend yield at 2.62% vs JPM's 1.86%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $35.62 | $418.50 | $339.75 | $103.64 | $342.55 |
| # AnalystsCovering analysts | 17 | 52 | 61 | 41 | 39 |
| Dividend YieldAnnual dividend ÷ price | — | +2.1% | +1.9% | +2.6% | +2.0% |
| Dividend StreakConsecutive years of raises | — | 16 | 15 | 0 | 5 |
| Dividend / ShareAnnual DPS | — | $8.70 | $5.95 | $2.67 | $6.06 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.5% | +3.9% | 0.0% | +4.6% |
JPM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CI leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
WAY vs UNH vs JPM vs CVS vs CI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is WAY or UNH or JPM or CVS or CI a better buy right now?
For growth investors, Waystar Holding Corp.
(WAY) is the stronger pick with 16. 5% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Cigna Corporation (CI) offers the better valuation at 13. 4x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — WAY or UNH or JPM or CVS or CI?
On trailing P/E, Cigna Corporation (CI) is the cheapest at 13.
4x versus CVS Health Corporation at 73. 4x. On forward P/E, Cigna Corporation is actually cheaper at 9. 8x.
03Which is the better long-term investment — WAY or UNH or JPM or CVS or CI?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -9. 4% for Waystar Holding Corp. (WAY). Over 10 years, the gap is even starker: JPM returned +465. 8% versus WAY's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — WAY or UNH or JPM or CVS or CI?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
19β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 394% more volatile than CVS relative to the S&P 500. On balance sheet safety, Waystar Holding Corp. (WAY) carries a lower debt/equity ratio of 39% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — WAY or UNH or JPM or CVS or CI?
By revenue growth (latest reported year), Waystar Holding Corp.
(WAY) is pulling ahead at 16. 5% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, WAY leads at 16. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — WAY or UNH or JPM or CVS or CI?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 2. 6% for CVS. At the gross margin level — before operating expenses — WAY leads at 64. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is WAY or UNH or JPM or CVS or CI more undervalued right now?
On forward earnings alone, Cigna Corporation (CI) trades at 9.
8x forward P/E versus 22. 2x for UnitedHealth Group Incorporated — 12. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WAY: 90. 0% to $35. 62.
08Which pays a better dividend — WAY or UNH or JPM or CVS or CI?
In this comparison, CVS (2.
6% yield), UNH (2. 1% yield), CI (2. 0% yield), JPM (1. 9% yield) pay a dividend. WAY does not pay a meaningful dividend and should not be held primarily for income.
09Is WAY or UNH or JPM or CVS or CI better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
19), 2. 6% yield). Both have compounded well over 10 years (CVS: +29. 5%, WAY: -9. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between WAY and UNH and JPM and CVS and CI?
These companies operate in different sectors (WAY (Technology) and UNH (Healthcare) and JPM (Financial Services) and CVS (Healthcare) and CI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: WAY is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; JPM is a large-cap deep-value stock; CVS is a mid-cap quality compounder stock; CI is a mid-cap deep-value stock. UNH, JPM, CVS, CI pay a dividend while WAY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.